» Authors » Trevin Kurtanich

Trevin Kurtanich

Explore the profile of Trevin Kurtanich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 32
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kang S, Mansurov A, Kurtanich T, Chun H, Slezak A, Volpatti L, et al.
J Immunother Cancer . 2025 Jan; 12(12). PMID: 39794939
Background: The use of immune checkpoint inhibitors (CPIs) has become a dominant regimen in modern cancer therapy, however immune resistance induced by tumor-associated macrophages (TAMs) with immune suppressive and evasion...
2.
Kang S, Mansurov A, Kurtanich T, Chun H, Slezak A, Volpatti L, et al.
Sci Adv . 2023 Nov; 9(48):eadh9879. PMID: 38019919
Cancer immunotherapy is moving toward combination regimens with agents of complementary mechanisms of action to achieve more frequent and robust efficacy. However, compared with single-agent therapies, combination immunotherapies are associated...
3.
Goldberger Z, Hauert S, Chang K, Kurtanich T, Alpar A, Repond G, et al.
Cell Rep Med . 2023 Aug; 4(8):101145. PMID: 37552990
Immune checkpoint immunotherapy (ICI) can re-activate immune reactions against neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a minority of patients are responsive to ICI, and approaches for...
4.
Hickman A, Koetsier J, Kurtanich T, Nielsen M, Winn G, Wang Y, et al.
J Clin Invest . 2022 May; 132(13). PMID: 35552271
The inability of CD8+ effector T cells (Teffs) to reach tumor cells is an important aspect of tumor resistance to cancer immunotherapy. The recruitment of these cells to the tumor...
5.
Kurtanich T, Roos N, Wang G, Yang J, Wang A, Chung E
SLAS Technol . 2018 Nov; 24(2):151-160. PMID: 30395768
Pancreatic cancer is one of the most lethal forms of cancer and has proven to be difficult to treat through conventional methods, including surgery and chemotherapy. Gene therapy serves as...